- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Page 665
Abalos attracts series A attention
Boehringer Ingelheim Venture Fund co-led a $13.3m round for the immuno-oncoclogy startup, which was spun out of University of Duisburg-Essen’s and University of Düsseldorf.
Oct 16, 2019Cyteir secures series B funding
The cancer therapy developer boosted a series B round led by Novo and backed by Celgene to $75.2m, with both corporates contributing to the latest tranche.
Oct 16, 2019Legend feeds series B funding to Gambol
Legend Capital and Industrial Bank have supplied $70.5m in series B funding for Gambol Pet Group, a pet food manufacturer with operations in Asia, the US and Europe.
Oct 16, 2019CleverTap wraps up $35m series C round
Returning investors Sequoia India and Tiger Global Management co-led a $35m round that valued Recruit-backed marketing software provider CleverTap at $385m.
Oct 16, 2019Cyteir takes series B to $75.2m
Jackson Laboratory cancer drug spinout Cyteir Therapeutics extended its series B round thanks to investors including Osage University Partners and Novo Holdings.
Oct 16, 2019Healx examines $56m series B
Atomico has led $56m series B round for Cambridge-allied rare disease therapy developer Healx, which also welcomed Intel Capital as a new shareholder.
Oct 16, 2019Sequis Life books $33m appointment with Alodokter
Sequis Life led a series C round for online healthcare and insurance portal Alodokter that included Philips and existing investor SoftBank Ventures Asia.
Oct 16, 2019Legend Capital stirs Mathpresso to series B
The SoftBank, Samsung and Megastudy-backed maths tutoring app developer secured $14.5m in a round led by Legend Capital.
Oct 16, 2019Provivi reaps $85m in series C round
BASF Venture Capital formed part of a consortium co-led by Pontifax Agtech and Temasek that supplied $85m in funding for pesticide developer Provivi.
Oct 15, 2019Ansun gets its hands on $80m
Lilly Asia Ventures returned for the respiratory disease drug developer's series B round, having co-led its $85m series A last year.
Oct 15, 2019About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits our membership, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


